ArticlePrzeglad gastroenterologiczny2026
The potential role of serum miR-182-5p and miR-127-5p in diagnosis of metabolic dysfunction-associated steatotic liver disease and its relationship with insulin resistance.
Article in Przeglad gastroenterologiczny, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Ellagic acid from the traditional Chinese medicinal herb Scutellaria barbata may accelerates apoptosis in hepatic stellate cells during liver fibrosis via inhibiting miR-182-5p.Molecular and cellular biochemistry · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The most widespread chronic hepatic illness nowadays is metabolic dysfunction-associated steatotic liver disease (MASLD), which has a higher risk of several complications including progression to metabolic dysfunction-associated steatohepatitis (MASH), cirrhosis, and hepatocellular carcinoma (HCC). New clinical research has established that microRNAs (miRNAs) are causative factors in the progression of MASLD, which could be used as diagnostic biomarkers and help in producing new treatment modalities. Material and methods: Sixty adult patients with MASLD and 50 healthy individuals were incorporated in the current work. Serum miR-182-5p and miR-127-5p expression levels were measured using quantitative real-time polymerase chain reaction (RT-PCR). Results: Compared to healthy controls, patients with MASLD exhibited significantly downregulated serum levels of miR-182-5p and miR-127-5p ( Conclusions: miR-182-5p and miR-127-5p could serve as novel biomarkers for MASLD diagnosis and may offer a novel approach for the disease's therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.